G9a: An Emerging Epigenetic Target for Melanoma Therapy.
Jessica L FlesherDavid E FisherPublished in: Epigenomes (2021)
Epigenetic regulation is a crucial component of DNA maintenance and cellular identity. As our understanding of the vast array of proteins that contribute to chromatin accessibility has advanced, the role of epigenetic remodelers in disease has become more apparent. G9a is a histone methyltransferase that contributes to immune cell differentiation and function, neuronal development, and has been implicated in diseases, including cancer. In melanoma, recurrent mutations and amplifications of G9a have led to its identification as a therapeutic target. The pathways that are regulated by G9a provide an insight into relevant biomarkers for patient stratification. Future work is aided by the breadth of literature on G9a function during normal differentiation and development, along with similarities to EZH2, another histone methyltransferase that forms a synthetic lethal relationship with members of the SWI/SNF complex in certain cancers. Here, we review the literature on G9a, its role in melanoma, and lessons from EZH2 inhibitor studies.
Keyphrases
- dna methylation
- gene expression
- systematic review
- skin cancer
- genome wide
- long non coding rna
- long noncoding rna
- papillary thyroid
- basal cell carcinoma
- transcription factor
- high resolution
- case report
- magnetic resonance
- current status
- circulating tumor
- bone marrow
- case control
- childhood cancer
- mesenchymal stem cells
- computed tomography
- oxidative stress